Fremont

Researchers are evaluating letrozole treatment in women newly diagnosed with uterine leiomyosarcoma, a type of cancer limited to the uterus. This randomized phase II study compares daily letrozole to observation to see if letrozole can extend the time patients remain free from disease progression. The main goal is to measure progression-free survival up to three years from randomization. Participants will be randomly assigned to receive either 2.5 mg of letrozole orally once daily or no treatment observation. The study includes patients with early-stage disease FIGO 2009 Stage I who have completed surgery with hysterectomy and bilateral salpingo-oophorectomy within 12 weeks before enrollment. The study uses adaptive randomization to assign patients to either group. During the trial, participants will be monitored regularly to detect any disease progression or death. The main measurement is the time from enrollment until progression or death. Participants must meet specific health criteria, including no measurable disease at enrollment and adequate organ function. The study will continue until July 2029, with primary outcome data collected up to three years after randomization.

This research aims to evaluate a brief PTSD treatment called Prolonged Exposure for Primary Care PE-PC among First Responders and Healthcare workers. The study compares this approach to standard care provided by Employee Assistance Programs EAPs to see if it reduces PTSD symptoms and improves functioning. The trial is sponsored by the University of Michigan and focuses on those with significant PTSD symptoms. Participants receive either the PE-PC treatment, which consists of 4 to 6 weekly 30-minute sessions delivered in person or by telehealth, or the usual EAP Treatment as Usual TAU which typically includes up to six solution-focused therapy sessions and referrals for specialized PTSD care. Both treatments involve homework and surveys, with progress reviewed at the end of the PE-PC sessions. The TAU groups care is monitored throughout the study, including outside treatments and medication use. Throughout the study, participants complete various surveys and homework assignments to track changes in PTSD symptoms, burnout, job performance, depressive symptoms, and patient satisfaction over six months. The main outcome measured is the change in PTSD symptom severity from baseline to six months. The study uses a randomized design and collects detailed monitoring data on treatment adherence and outcomes during this period.